FR2487196A1 - Composition pharmaceutique produisant des effets diuretiques, hypotenseurs et anti-oedemateux a base de derive quinoleinique - Google Patents
Composition pharmaceutique produisant des effets diuretiques, hypotenseurs et anti-oedemateux a base de derive quinoleinique Download PDFInfo
- Publication number
- FR2487196A1 FR2487196A1 FR8114439A FR8114439A FR2487196A1 FR 2487196 A1 FR2487196 A1 FR 2487196A1 FR 8114439 A FR8114439 A FR 8114439A FR 8114439 A FR8114439 A FR 8114439A FR 2487196 A1 FR2487196 A1 FR 2487196A1
- Authority
- FR
- France
- Prior art keywords
- oximino
- tetrahydroquinoline
- chloro
- tetrahydro
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 12
- 230000001882 diuretic effect Effects 0.000 title claims abstract description 11
- 239000002934 diuretic Substances 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title description 7
- 230000003501 anti-edematous effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 50
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000001077 hypotensive effect Effects 0.000 claims description 9
- 229920000084 Gum arabic Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000000205 acacia gum Substances 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000021822 hypotensive Diseases 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- YSEKTWYSDQTJBX-JLHYYAGUSA-N 1-[(4E)-6-bromo-4-hydroxyimino-2,3-dihydroquinolin-1-yl]ethanone Chemical compound CC(=O)N1CC\C(=N/O)c2cc(Br)ccc12 YSEKTWYSDQTJBX-JLHYYAGUSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- CCFGZXKGAMQZAW-UVTDQMKNSA-N (4z)-6-bromo-4-hydroxyimino-n,n-dimethyl-2,3-dihydroquinoline-1-carboxamide Chemical compound BrC1=CC=C2N(C(=O)N(C)C)CC\C(=N\O)C2=C1 CCFGZXKGAMQZAW-UVTDQMKNSA-N 0.000 claims 1
- ZUCXFPUJJXJECB-UVTDQMKNSA-N (4z)-6-chloro-4-hydroxyimino-n,n-dimethyl-2,3-dihydroquinoline-1-carboxamide Chemical compound ClC1=CC=C2N(C(=O)N(C)C)CC\C(=N\O)C2=C1 ZUCXFPUJJXJECB-UVTDQMKNSA-N 0.000 claims 1
- CNLSVGAHIXRIEE-UVTDQMKNSA-N (4z)-6-fluoro-4-hydroxyimino-n,n-dimethyl-2,3-dihydroquinoline-1-carboxamide Chemical compound FC1=CC=C2N(C(=O)N(C)C)CC\C(=N\O)C2=C1 CNLSVGAHIXRIEE-UVTDQMKNSA-N 0.000 claims 1
- NLZMOZGKKLOJEM-LDKJASCWSA-N (e)-1-[(4z)-6-bromo-4-hydroxyimino-2,3-dihydroquinolin-1-yl]-3-phenylprop-2-en-1-one Chemical compound C12=CC=C(Br)C=C2C(=N/O)\CCN1C(=O)\C=C\C1=CC=CC=C1 NLZMOZGKKLOJEM-LDKJASCWSA-N 0.000 claims 1
- PFBRRAPCLHIKEE-LDKJASCWSA-N (e)-1-[(4z)-6-chloro-4-hydroxyimino-2,3-dihydroquinolin-1-yl]-3-phenylprop-2-en-1-one Chemical compound C12=CC=C(Cl)C=C2C(=N/O)\CCN1C(=O)\C=C\C1=CC=CC=C1 PFBRRAPCLHIKEE-LDKJASCWSA-N 0.000 claims 1
- ABELRHWKDXLRAR-UHFFFAOYSA-N 1-(6-chloro-4-hydroxyimino-2,3-dihydroquinolin-1-yl)propan-1-one Chemical compound ClC1=CC=C2N(C(=O)CC)CCC(=NO)C2=C1 ABELRHWKDXLRAR-UHFFFAOYSA-N 0.000 claims 1
- NQKGMBOMDGBMRP-PTNGSMBKSA-N 1-[(4z)-6-bromo-4-hydroxyimino-2,3-dihydroquinolin-1-yl]-2-methylpropan-1-one Chemical compound BrC1=CC=C2N(C(=O)C(C)C)CC\C(=N\O)C2=C1 NQKGMBOMDGBMRP-PTNGSMBKSA-N 0.000 claims 1
- NXXUQBZRZORLTJ-UVTDQMKNSA-N 1-[(4z)-6-bromo-4-hydroxyimino-2,3-dihydroquinolin-1-yl]propan-1-one Chemical compound BrC1=CC=C2N(C(=O)CC)CC\C(=N\O)C2=C1 NXXUQBZRZORLTJ-UVTDQMKNSA-N 0.000 claims 1
- AELVWPPXVWMAFZ-CYVLTUHYSA-N 1-[(4z)-6-chloro-4-hydroxyimino-2,3-dihydroquinolin-1-yl]-2-phenylethanone Chemical compound C12=CC=C(Cl)C=C2C(=N/O)\CCN1C(=O)CC1=CC=CC=C1 AELVWPPXVWMAFZ-CYVLTUHYSA-N 0.000 claims 1
- AHNPJQHOUHIVKU-VBKFSLOCSA-N 1-[(4z)-6-chloro-4-hydroxyimino-2,3-dihydroquinolin-1-yl]-3-methylbutan-1-one Chemical compound ClC1=CC=C2N(C(=O)CC(C)C)CC\C(=N\O)C2=C1 AHNPJQHOUHIVKU-VBKFSLOCSA-N 0.000 claims 1
- NJNLNQPIKSHXQP-RAXLEYEMSA-N 1-[(4z)-6-chloro-4-hydroxyimino-2,3-dihydroquinolin-1-yl]ethanone Chemical compound ClC1=CC=C2N(C(=O)C)CC\C(=N\O)C2=C1 NJNLNQPIKSHXQP-RAXLEYEMSA-N 0.000 claims 1
- FEGWEZYQHKCBKL-UVTDQMKNSA-N 1-[(4z)-6-fluoro-4-hydroxyimino-2,3-dihydroquinolin-1-yl]propan-1-one Chemical compound FC1=CC=C2N(C(=O)CC)CC\C(=N\O)C2=C1 FEGWEZYQHKCBKL-UVTDQMKNSA-N 0.000 claims 1
- UIBXXPJWUJOKGG-UHFFFAOYSA-N 6-chloro-4-hydroxyimino-n-methyl-2,3-dihydroquinoline-1-carboxamide Chemical compound ClC1=CC=C2N(C(=O)NC)CCC(=NO)C2=C1 UIBXXPJWUJOKGG-UHFFFAOYSA-N 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- CXHKFCSPBVOEMA-UVTDQMKNSA-N ethyl (4z)-6-chloro-4-hydroxyimino-2,3-dihydroquinoline-1-carboxylate Chemical compound ClC1=CC=C2N(C(=O)OCC)CC\C(=N\O)C2=C1 CXHKFCSPBVOEMA-UVTDQMKNSA-N 0.000 claims 1
- HVADSRDRNLXETI-UVTDQMKNSA-N ethyl (4z)-6-fluoro-4-hydroxyimino-2,3-dihydroquinoline-1-carboxylate Chemical compound FC1=CC=C2N(C(=O)OCC)CC\C(=N\O)C2=C1 HVADSRDRNLXETI-UVTDQMKNSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- MYOLFGKGSLHSOH-LCYFTJDESA-N methyl (4z)-6-bromo-4-hydroxyimino-2,3-dihydroquinoline-1-carboxylate Chemical compound BrC1=CC=C2N(C(=O)OC)CC\C(=N\O)C2=C1 MYOLFGKGSLHSOH-LCYFTJDESA-N 0.000 claims 1
- IXZVOELNROZATN-LCYFTJDESA-N methyl (4z)-6-fluoro-4-hydroxyimino-2,3-dihydroquinoline-1-carboxylate Chemical compound FC1=CC=C2N(C(=O)OC)CC\C(=N\O)C2=C1 IXZVOELNROZATN-LCYFTJDESA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 22
- 239000013078 crystal Substances 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 208000004880 Polyuria Diseases 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 244000215068 Acacia senegal Species 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- -1 carboxymethyl- Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 2
- 230000004526 pharmaceutical effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YUGVRNDMXFUNIP-UHFFFAOYSA-N 1-acetyl-6-bromo-2,3-dihydroquinolin-4-one Chemical compound BrC1=CC=C2N(C(=O)C)CCC(=O)C2=C1 YUGVRNDMXFUNIP-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical compound [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 description 1
- SSZWWUDQMAHNAQ-UHFFFAOYSA-N 3-chloropropane-1,2-diol Chemical compound OCC(O)CCl SSZWWUDQMAHNAQ-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- HDPQYTNPAOFFEA-UHFFFAOYSA-N C(=O)=C1NC2=CC=CC=C2CC1 Chemical compound C(=O)=C1NC2=CC=CC=C2CC1 HDPQYTNPAOFFEA-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10327380A JPS5728005A (en) | 1980-07-28 | 1980-07-28 | Pharmaceutical composition having diuretic, hypotensive and antihydropic activity |
| JP3990981A JPS57154167A (en) | 1981-03-19 | 1981-03-19 | Pharmaceutical composition having diuretic, hypotensive and antihydropic activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2487196A1 true FR2487196A1 (fr) | 1982-01-29 |
| FR2487196B1 FR2487196B1 (cg-RX-API-DMAC7.html) | 1984-12-28 |
Family
ID=26379310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8114439A Granted FR2487196A1 (fr) | 1980-07-28 | 1981-07-24 | Composition pharmaceutique produisant des effets diuretiques, hypotenseurs et anti-oedemateux a base de derive quinoleinique |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE3129719C2 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2487196A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2081091B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839368A (en) * | 1986-05-02 | 1989-06-13 | Mochida Pharmaceutical Co., Ltd. | 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives |
| JP2602037B2 (ja) * | 1987-10-31 | 1997-04-23 | 持田製薬株式会社 | １−アシル−２，３−ジヒドロ−４（１ｈ）−キノリノン−４−オキシム誘導体、その製法およびそれらを主成分とする利尿、降圧、抗浮腫および腹水除去用医薬組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3406176A (en) * | 1964-08-24 | 1968-10-15 | Sterling Drug Inc | 7-halo-4-carbamylimino-1, 4-dihydroquinolines |
-
1981
- 1981-07-07 GB GB8120930A patent/GB2081091B/en not_active Expired
- 1981-07-24 FR FR8114439A patent/FR2487196A1/fr active Granted
- 1981-07-28 DE DE19813129719 patent/DE3129719C2/de not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3406176A (en) * | 1964-08-24 | 1968-10-15 | Sterling Drug Inc | 7-halo-4-carbamylimino-1, 4-dihydroquinolines |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3129719A1 (de) | 1982-03-18 |
| GB2081091A (en) | 1982-02-17 |
| GB2081091B (en) | 1984-03-07 |
| FR2487196B1 (cg-RX-API-DMAC7.html) | 1984-12-28 |
| DE3129719C2 (de) | 1984-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2538386A1 (fr) | Nouveaux amides et imides carboxyliques procedes pour leur preparation et composition pharmaceutique les contenant | |
| FR2532844A1 (fr) | Composition pharmaceutique contenant un compose polyprenylique | |
| CA1213892A (fr) | Procede de preparation de nouveaux derives de la sulfonyluree | |
| LU81565A1 (fr) | Nouvelles imidazoquinoxalines et leurs sels,leur procede de preparation,leur application a titre de medicaments et les compositions pharmaceutiques les renfermant | |
| CA1142521A (fr) | Procede de preparation de nouveaux derives de l'oxoimidazoquinoxaline | |
| CH648285A5 (fr) | Acides benzoyl-3-nitro-2-phenylacetiques et sels metalliques, amides et esters correspondants utiles notamment comme medicaments anti-inflammatoires, procede et composes pour leur preparation. | |
| MC1255A1 (fr) | L'acide 7-methoxy-5-oxo-5h-thiazolo(2,3-b)quinazoline-2-carboxylique et ses sels,leur preparation et leurs utilisations therapeutiques | |
| LU83928A1 (fr) | Acides amino-2 halogenobenzoyl-3 methyphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques | |
| FR2487196A1 (fr) | Composition pharmaceutique produisant des effets diuretiques, hypotenseurs et anti-oedemateux a base de derive quinoleinique | |
| FR2637596A1 (fr) | Methyl-4 ((aryl-4 piperazinyl-1)-2 ethyl)-5 thiazole et ses derives, leur procede de preparation et les medicaments en contenant | |
| CA1146559A (fr) | Procede de preparation de nouveaux derives du tetrahydropyridin-4-yl indole et de leurs sels | |
| LU83713A1 (fr) | Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant | |
| EP0001947A1 (fr) | Dérivés de l'amino-2 thiazoline, procédé de préparation et compositions pharmaceutiques les contenant | |
| BE1003692A4 (fr) | Composes de pyrrolidinone et de piperidinone et compositions pharmaceutiques les contenant. | |
| US4440770A (en) | Diuretic, hypotensive and antiedemic quinoline oximes | |
| EP0347305B1 (fr) | [(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif | |
| LU83273A1 (fr) | Thiazoles | |
| CA1263391A (fr) | N-carboxyalcoyl-2 oxo-3 diaryl 5-6 triazines utiles en therapeutique | |
| EP0209435A1 (fr) | Dérivés de l'hydroxy alkoxy 4-phénylpropyl indole, leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments et compositions les renfermant | |
| LU82672A1 (fr) | Acides 2-amino-3-(alkylthiobenzoyl)-phenylacetiques et derives,et leur utilisation comme anti-inflammatoires,analgesiques,et inhibant l'agglomeration des plaquettes sanguines | |
| BE882414A (fr) | Nouveaux acides et esters 4-amino-3-quinoleine-carboxyliques, utiles notamment comme agents antisecretoires et anti-ulcere | |
| FR2566407A1 (fr) | Nouveaux derives de l'isoxazoloquinoleine, procede de preparation, application a titre de medicaments, et compositions les renfermant | |
| CA1106376A (fr) | Procede de preparation de nouveaux esters anthraniliques | |
| EP0647221A1 (fr) | Aryl-1 (o-alcoxyphenyl-4 piperazinyl-1)-2, -3 ou -4 alcanols, leur procede de preparation et leur utilisation pour la preparation de medicaments | |
| EP0187551A1 (fr) | Dérivés de la pyrazolo/4,3-c/cinnolin-3-one, leurs sels, procédé de préparation, application à titre de médicaments, compositions les renfermant et produits intermédiaires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |